Combivir is a combination antiretroviral medication used in the treatment of hiv infection. It contains lamivudine and zidovudine, which are nucleoside reverse transcriptase inhibitors. The drug works by inhibiting the viral reverse transcriptase enzyme that copies hiv rna into dna. Lamivudine is incorporated into the growing viral dna chain and prevents its elongation. Zidovudine also acts as a chain terminator by lacking a 3' hydroxyl group needed for further nucleoside addition. By blocking reverse transcriptase both components reduce the rate of viral replication in infected cells. This reduction in viral replication slows the progression of hiv disease in patients. The combined effect provides a synergistic decline in plasma hiv rna levels and increases cd4 cell counts.

Combivir is a fixed dose combination medication that contains lamivudine and zidovudine for the treatment of hiv infection. It is classified as an antiretroviral drug that helps control viral replication in patients with hiv. Lamivudine works by inhibiting the viral reverse transcriptase enzyme, preventing the virus from copying its genetic material. Zidovudine also targets reverse transcriptase but does so by acting as a nucleoside analog that terminates the growing viral dna chain. Together the two agents produce a synergistic suppression of hiv replication, reducing the amount of virus in the bloodstream. By lowering viral load, Combivir helps maintain immune function and slows the progression of aids related disease. The combined pharmacological action of the two nucleoside reverse transcriptase inhibitors provides a comprehensive approach to managing hiv infection.

Combivir may cause nausea in some patients. Headache is a frequently reported symptom. Fatigue can occur during treatment. Some individuals experience abdominal discomfort. Insomnia or difficulty sleeping has been observed. Skin rash may develop as a reaction.

Combivir may cause nausea in some patients. It can lead to fatigue that varies in intensity. Headache is a common complaint reported by users. Skin rash may develop as an allergic response. Some individuals experience coughing or shortness of breath. Dizziness can occur, sometimes accompanied by lightheadedness. Peripheral neuropathy may manifest as tingling in the extremities. Laboratory abnormalities, such as changes in liver enzymes, have also been observed.